Evaluation of potential drug interactions in hospital admission

In clinical practice, drugs association is common and can lead to drug interactions (MI), which can lead to an avoidable adverse events that may need a for pharmaceutical intervention. Objective: The objective of this study is to identify and evaluate the drug interactions present on prescriptions of patients at the adult medical clinic of a hospital in Rio de Janeiro, at admission moment. Method: Cross-sectional study involving the analysis of information through the database (e-sus). Interactions were classified according to the Micromedex database. Results: A total of 177 prescriptions were evaluated. The main underlying disease was the neoplasias (36.16%), and the main cause of hospitalization was pain (8.5%). Of the prescriptions evaluated, 81.93% had some potential MI. A total of 180 types of MI were identified, representing 600 IM. Considering the degree of severity, 60% (358) were classified as severe MI, 38% (229) moderate, 1% (7) low and contraindicated. The most prevalent drug involved in MI was dipyrone (43.8%). The most frequent severe MI was between Dipirona + Enoxaparin (9.4%). Among moderate MI, Dipirone + Captopril (14.8%) was the most frequent and among the low ones, Furosemide + Hydralazine (42.9%). The contraindicated MI appeared in a similar way with 16.7% each. According to the scientific evidence found, serious MI had mostly reasonable documentation (59.5%), while the moderate ones had the majority of documentation classified as good (48.9%). Conclusion: In this context it is reasonable to consider that the pharmaceutical analysis of prescription at the patient admission may contribute to preventing drug-related adverse events.